化学
激酶
共价键
生物化学
半胱氨酸
半胱氨酸蛋白酶抑制剂
药物开发
药物发现
精氨酸
酶
结构-活动关系
抗药性
限制
酶抑制剂
铅化合物
药理学
共价结合
药品
苯乙二醛
点突变
作者
Zuqin Wang,Xuan Wang,Hong Zhang,Jiahuan He,Lu Wang,Ling Li,Peng Chen,Jibo Kang,Xiaojuan Song,Zhengchao Tu,Zhang Zhang,Zhimin Zhang,Shao Qin Yao,Xiaoyun Lu
标识
DOI:10.1021/acs.jmedchem.6c01581
摘要
Covalent kinase inhibitors (CKIs) serve as potent therapeutics, yet their development largely depends on conserved cysteine residues. Many kinases lack accessible cysteines or develop resistance mutations at these sites, limiting clinical utility. To diversify targetable nucleophilic amino acids, we developed a modular strategy for arginine reactive CKIs using two warhead types: O-cyanobenzaldehyde (CNBA) and phenylglyoxal (PGO). We first synthesized RA2, a CNBA-based AURKA inhibitor targeting arginine (R220), which showed weak cellular activity (GI50 > 2 μM). Using PGO warhead, we generated covalent inhibitors C1 against ALK-G1202R and L1a against TRKA-G595R; both strongly inhibited arginine-mutant kinases but showed unsatisfactory cellular potency. Further optimization of PGO electrophilicity via methoxy substitution yielded L1c, which exhibited potent cellular activity (GI50 = 0.39 μM) against drug-resistant Ba/F3-CD74-TRKA-G595R cells and sustained target engagement. Collectively, this work expands the CKI toolbox to include arginine-targeting warheads and provides a modular framework to overcome point mutation-driven resistance.
科研通智能强力驱动
Strongly Powered by AbleSci AI